nach oben

Erschienen in:

02.08.2021 | Original Article

Revisiting vimentin: a negative surrogate marker of molecularly defined oligodendroglioma in adult type diffuse glioma

verfasst von: Seong-Ik Kim, Kwanghoon Lee, Jeongmo Bae, Sungyoung Lee, Hongseok Yun, Chul-Kee Park, Seung Hong Choi, Christopher Alec Maquiling, Sung-Hye Park, Jae-Kyung Won

Erschienen in: Brain Tumor Pathology | Ausgabe 4/2021

Einloggen, um Zugang zu erhalten

Abstract

Vimentin is a marker of epithelial-mesenchymal transformation and indicates poor prognosis in various cancers, but its role in diffuse gliomas remains unknown. We investigated the vimentin expression of diffuse gliomas according to the upcoming 2021 WHO classification, its variations due to mutational status, and its prognostic effects. We analyzed vimentin immunohistochemistry in 315 gliomas: a test set (n = 164) and a validation set (n = 151). RNA-seq and mutational information from The Cancer Genome Atlas (TCGA, n = 422) were also used for validation. Vimentin was diffusely positive in astrocytic tumors but negative in oligodendroglial tumors (ODGs) and its expression was significantly higher in isocitrate dehydrogenase (IDH) wild-type tumors. High vimentin expression was correlated with poor prognosis (hazard ratio [HR]: 5.99), but it was dependent on the new WHO grade which reflects both histologic features and genetics (HR: 1.28). Using the significant difference in vimentin expression between ODGs and astrocytic tumors, the positive and negative predictive values of the vimentin-based diagnosis for ODGs were 93.5% and 97.8% in the validation set. Along with additional alpha-thalassemia/mental retardation, X-linked (ATRX) immunohistostaining, the values were 98.3% and 97.8%, respectively. Vimentin is a useful ancillary marker for identifying ODGs when combined with routine histochemistry markers.

Nur mit Berechtigung zugänglich

Ceccarelli M, Barthel FP, Malta TM et al (2016) Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell 164:550–563. https://doi.org/10.1016/j.cell.2015.12.028CrossRefPubMedPubMedCentral

Louis DN, Perry A, Reifenberger G et al (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol (Berl) 131:803–820. https://doi.org/10.1007/s00401-016-1545-1CrossRef

Louis DN, Wesseling P, Aldape K et al (2020) cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading. Brain Pathol Zurich Switz 30:844–856. https://doi.org/10.1111/bpa.12832CrossRef

Phillips HS, Kharbanda S, Chen R et al (2006) Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9:157–173. https://doi.org/10.1016/j.ccr.2006.02.019CrossRefPubMed

Verhaak RGW, Hoadley KA, Purdom E et al (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98–110. https://doi.org/10.1016/j.ccr.2009.12.020CrossRefPubMedPubMedCentral

Behnan J, Finocchiaro G, Hanna G (2019) The landscape of the mesenchymal signature in brain tumours. Brain J Neurol 142:847–866. https://doi.org/10.1093/brain/awz044CrossRef

Abaza MS, Shaban F, Narayan RK, Atassi MZ (1998) Human glioma associated intermediate filament proteins: over-expression, co-localization and cross-reactivity. Anticancer Res 18:1333–1340PubMed

Andersson D, Wilhelmsson U, Nilsson M et al (2013) Plasticity response in the contralesional hemisphere after subtle neurotrauma: gene expression profiling after partial deafferentation of the hippocampus. PLoS ONE 8:e70699. https://doi.org/10.1371/journal.pone.0070699CrossRefPubMedPubMedCentral

Hutchins JB, Casagrande VA (1989) Vimentin: changes in distribution during brain development. Glia 2:55–66. https://doi.org/10.1002/glia.440020107CrossRefPubMed

10.

Herpers MJ, Ramaekers FC, Aldeweireldt J et al (1986) Co-expression of glial fibrillary acidic protein- and vimentin-type intermediate filaments in human astrocytomas. Acta Neuropathol (Berl) 70:333–339. https://doi.org/10.1007/BF00686093CrossRef

11.

Kang YH, Han SR, Jeon H et al (2019) Nogo receptor–vimentin interaction: a novel mechanism for the invasive activity of glioblastoma multiforme. Exp Mol Med 51:1–15. https://doi.org/10.1038/s12276-019-0332-1CrossRefPubMed

12.

Nowicki MO, Hayes JL, Chiocca EA, Lawler SE (2019) Proteomic analysis implicates vimentin in glioblastoma cell migration. Cancers 11:466. https://doi.org/10.3390/cancers11040466CrossRefPubMedCentral

13.

Nakopoulou L, Kerezoudi E, Thomaides T, Litsios B (1990) An immunocytochemical comparison of glial fibrillary acidic protein, S-100p and vimentin in human glial tumors. J Neurooncol 8:33–40. https://doi.org/10.1007/BF00182084CrossRefPubMed

14.

Dehghani F, Schachenmayr W, Laun A, Korf HW (1998) Prognostic implication of histopathological, immunohistochemical and clinical features of oligodendrogliomas: a study of 89 cases. Acta Neuropathol (Berl) 95:493–504. https://doi.org/10.1007/s004010050830CrossRef

15.

Lin L, Wang G, Ming J et al (2016) Analysis of expression and prognostic significance of vimentin and the response to temozolomide in glioma patients. Tumour Biol J Int Soc Oncodevelopmental Biol Med 37:15333–15339. https://doi.org/10.1007/s13277-016-5462-7CrossRef

16.

Lassman AB, Roberts-Rapp L, Sokolova I et al (2019) Comparison of biomarker assays for EGFR: implications for precision medicine in patients with glioblastoma. Clin Cancer Res 25:3259–3265. https://doi.org/10.1158/1078-0432.CCR-18-3034CrossRefPubMedPubMedCentral

17.

Pirker R, Pereira JR, von Pawel J et al (2012) EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol 13:33–42. https://doi.org/10.1016/S1470-2045(11)70318-7CrossRefPubMed

18.

Santosh N, McNamara KK, Beck FM, Kalmar JR (2019) Expression of cornulin in oral premalignant lesions. Oral Surg Oral Med Oral Pathol Oral Radiol 127:526–534. https://doi.org/10.1016/j.oooo.2019.02.003CrossRefPubMed

19.

Cerami E, Gao J, Dogrusoz U et al (2012) The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2:401–404. https://doi.org/10.1158/2159-8290.CD-12-0095CrossRefPubMed

20.

Gao J, Aksoy BA, Dogrusoz U et al (2013) Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6:pl1. https://doi.org/10.1126/scisignal.2004088CrossRefPubMedPubMedCentral

21.

Weller M, van den Bent M, Tonn JC et al (2017) European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol 18:e315–e329. https://doi.org/10.1016/S1470-2045(17)30194-8CrossRefPubMed

22.

Koperek O, Gelpi E, Birner P et al (2004) Value and limits of immunohistochemistry in differential diagnosis of clear cell primary brain tumors. Acta Neuropathol (Berl) 108:24–30. https://doi.org/10.1007/s00401-004-0856-9CrossRef

23.

Herpers MJ, Budka H (1984) Glial fibrillary acidic protein (GFAP) in oligodendroglial tumors: gliofibrillary oligodendroglioma and transitional oligoastrocytoma as subtypes of oligodendroglioma. Acta Neuropathol (Berl) 64:265–272. https://doi.org/10.1007/BF00690392CrossRef

24.

Reuss DE, Sahm F, Schrimpf D et al (2015) ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an “integrated” diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Acta Neuropathol (Berl) 129:133–146. https://doi.org/10.1007/s00401-014-1370-3CrossRef

25.

Gillet E, Alentorn A, Doukouré B et al (2014) TP53 and p53 statuses and their clinical impact in diffuse low grade gliomas. J Neurooncol 118:131–139. https://doi.org/10.1007/s11060-014-1407-4CrossRefPubMed

26.

Gomes FC, Paulin D, Moura Neto V (1999) Glial fibrillary acidic protein (GFAP): modulation by growth factors and its implication in astrocyte differentiation. Braz J Med Biol Res Rev Bras Pesqui Medicas Biol 32:619–631. https://doi.org/10.1590/s0100-879x1999000500016CrossRef

27.

Louis DN (2009) Non-neoplastic diseases of the central nervous system. American Registry of Pathology, Washington, DC

28.

Satelli A, Li S (2011) Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell Mol Life Sci CMLS 68:3033–3046. https://doi.org/10.1007/s00018-011-0735-1CrossRefPubMed

29.

Zhao J, Zhang L, Dong X et al (2018) High expression of vimentin is associated with progression and a poor outcome in glioblastoma. Appl Immunohistochem Mol Morphol 26:337–344. https://doi.org/10.1097/PAI.0000000000000420CrossRefPubMed

30.

Wang Q, Hu B, Hu X et al (2017) Tumor evolution of glioma-intrinsic gene expression subtypes associates with immunological changes in the microenvironment. Cancer Cell 32:42-56.e6. https://doi.org/10.1016/j.ccell.2017.06.003CrossRefPubMedPubMedCentral

31.

Bhat KPL, Balasubramaniyan V, Vaillant B et al (2013) Mesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastoma. Cancer Cell 24:331–346. https://doi.org/10.1016/j.ccr.2013.08.001CrossRefPubMed

32.

Fedele V, Dai F, Masilamani AP et al (2017) Epigenetic regulation of ZBTB18 promotes glioblastoma progression. Mol Cancer Res MCR 15:998–1011. https://doi.org/10.1158/1541-7786.MCR-16-0494CrossRefPubMed

33.

Wu G, Diaz AK, Paugh BS et al (2014) The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. Nat Genet 46:444–450. https://doi.org/10.1038/ng.2938CrossRefPubMedPubMedCentral

34.

Ellison DW, Hawkins C, Jones DTW et al (2019) cIMPACT-NOW update 4: diffuse gliomas characterized by MYB, MYBL1, or FGFR1 alterations or BRAFV600E mutation. Acta Neuropathol (Berl) 137:683–687. https://doi.org/10.1007/s00401-019-01987-0CrossRef

35.

Ebrahimi A, Skardelly M, Bonzheim I et al (2016) ATRX immunostaining predicts IDH and H3F3A status in gliomas. Acta Neuropathol Commun 4:60. https://doi.org/10.1186/s40478-016-0331-6CrossRefPubMedPubMedCentral

Titel: Revisiting vimentin: a negative surrogate marker of molecularly defined oligodendroglioma in adult type diffuse glioma
verfasst von: Seong-Ik Kim
Kwanghoon Lee
Jeongmo Bae
Sungyoung Lee
Hongseok Yun
Chul-Kee Park
Seung Hong Choi
Christopher Alec Maquiling
Sung-Hye Park
Jae-Kyung Won
Publikationsdatum: 02.08.2021
Verlag: Springer Singapore
Erschienen in: Brain Tumor Pathology / Ausgabe 4/2021
Print ISSN: 1433-7398
Elektronische ISSN: 1861-387X
DOI: https://doi.org/10.1007/s10014-021-00411-4

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

25.04.2024 | Hypotonie | Nachrichten

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Revisiting vimentin: a negative surrogate marker of molecularly defined oligodendroglioma in adult type diffuse glioma

Abstract

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Frühe Alzheimertherapie lohnt sich

Viel Bewegung in der Parkinsonforschung

Demenzkranke durch Antipsychotika vielfach gefährdet

Update Neurologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Frühe Alzheimertherapie lohnt sich

Viel Bewegung in der Parkinsonforschung

Demenzkranke durch Antipsychotika vielfach gefährdet

Update Neurologie